Dolutegravir/lamivudine/tenofovir

Dolutegravir/lamivudine/tenofovir is a fixed-dose combination of antiretroviral drugs used in the treatment of HIV/AIDS. This combination is recommended by the World Health Organization for initial treatment of people with HIV, as well as for those who have previously received antiretroviral therapy.

Composition

The combination includes three active ingredients: dolutegravir, lamivudine, and tenofovir. Dolutegravir is an integrase inhibitor, which prevents the virus from integrating its genetic material into the host cell. Lamivudine and tenofovir are both nucleoside reverse transcriptase inhibitors, which block a different step in the virus's replication cycle.

Usage

Dolutegravir/lamivudine/tenofovir is taken once daily, with or without food. The combination is available in tablet form, and the dose is the same for adults and children aged 12 years and older.

Side Effects

Common side effects include headache, diarrhea, and nausea. Serious side effects may include liver problems, kidney problems, and a build-up of lactic acid in the blood.

Interactions

Dolutegravir/lamivudine/tenofovir can interact with a number of other medications, including certain antacids, anticonvulsants, and antibiotics. It is important to tell your healthcare provider about all the medications you are taking.

Availability

Dolutegravir/lamivudine/tenofovir is available in many countries worldwide. In some countries, it is available as a generic medication.

See Also

• Antiretroviral therapy
• HIV/AIDS
• World Health Organization